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Background: Increased activation of mammalian target of rapamycin (mTOR) is observed in numerous human
cancers. Recent studies on the glioma kinome have identified several deregulated pathways that converge and
activate mTOR. The available evidence on the role of microglia in CNS cancers would suggest a dual role, a
tumoricidal role and -on the contrary- a role favoring tumor growth.
Methods: In the present paper, we have compared the effects of μM concentrations of rapamycin (RAPA) and its analog,
RAD001 (RAD), on activated microglia; the latter was obtained by exposing cells to conditioned medium harvested either
from inflammatory activated glioma cells (LI-CM) or from glioma cells kept under basal conditions (C-CM).
Results: Here we show that the inhibition of mTOR polarizes glioma-activated microglial cells towards the M1 phenotype,
with cytotoxic activities, preventing the induction of the M2 status that promotes tumor growth. In fact RAPA and RAD
significantly increased iNOS expression and activity, while on the same time significantly reducing IL-10 gene expression
induced by C-CM, thus suggesting that the drugs prevent the acquisition of a M2 phenotype in response to glioma
factors promoting a classic M1 activation. Similar results were obtained using the conditioned media obtained after
glioma stimulation with LPS-IFNγ (LI-CM), which was found to induce a mixture of M1 and M2a/b polarization phenotypes.
In these conditions, the inhibition of mTOR led to a significant up-regulation of iNOS, and in parallel to the
down-regulation of both ARG and IL-10 gene expression.
Conclusions: These data suggest that mTOR inhibition may prevent glioma induced M2 polarization of
microglial cells and increase their cytotoxic potential, possibly resulting in antitumor actions.Introduction
The mammalian target of rapamycin (mTOR) is a
conserved serine/threonine protein kinase involved in
the regulation of multiple intracellular processes such as
mRNA transcription and translation, ribosomal biogenesis,
lipid biosynthesis, energy metabolism, autophagy and
cytoskeletal organization [1]. Within the cells two distinct
complexes, namely mTORC1 and mTORC2, are expressed,
that are associated to different partners [2]. Increased
activation of mTORC1 is observed in numerous human
cancers due to gain-of-function mutations in oncogenes
(PI3K, AKT or Ras) and/or loss-of-function mutations in
tumor suppressors (PTEN, LKB1, or TSC1/2), upstream
regulators of mTORC1 [3]. These mutations provide cancer* Correspondence: pnavarra@rm.unicatt.it
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unless otherwise stated.cells with a selective growth advantage in comparison to
normal cells [4]. On the other hand, mTORC2 is associated
with cell adhesion and migration, thus mainly with tumor
invasion of normal tissue [5].
Glioblastomas (GBM, World Health Organization
(WHO) IV astrocytomas) are the most common and
aggressive primary central nervous system (CNS) tumors,
originating from glial cells and characterized by morpho-
logical and genetic complexity [6]. Current therapeutic
strategies (that is, aggressive surgical resection combined
with radiation and chemotherapy) are largely ineffective;
tumors often recur and are invariably fatal, with a median
survival of 12 to 15 months from diagnosis [7]. Recent stud-
ies on the glioma kinome have identified several deregulated
pathways that converge and activate mTOR [8].
Despite the central role of mTOR in glioma biology,
mTORC1 inhibitors, like rapamycin (RAPA) and its analogs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical trials [8], with the exception of RAD001 in pediatric
patients affected by subependymal giant-cell astrocytomas
(WHO I astrocytomas) [9]. The reasons for the limited
clinical success of rapalogs (in glioma but also in major
solid tumors) have not been clarified but are likely related
to the inhibition of a large number of mTORC1-regulated
signaling systems normally involved in tumor suppression,
such as the activation of receptor tyrosine kinases (RTKs),
PI3K-Akt signaling, and the Ras-ERK pathway [10].
Moreover, rapamycin is unable to inhibit all the downstream
targets of mTORC1 and to significantly suppress
mTORC2 signaling [11]. In order to by-pass these
limitations, alternative strategies have been explored in
the past few years and a number of ATP-competitive
mTOR inhibitors have been developed, which block both
mTORC1 and mTORC2 activity. Interestingly, because of
the high sequence homology between mTOR and PI3K,
some compounds originally identified as PI3K inhibitors
were later shown to inhibit mTOR as well [10]. Unlike
RAPA, which is a specific allosteric inhibitor of mTORC1,
these ATP-competitive inhibitors target the catalytic
site of the enzyme, thus promoting a broader, more potent
and sustained inhibition of mTOR, and preventing the
activation of PI3K/Akt caused by the de-repression of
negative feedbacks [12]. At present, ClinicalTrials.gov lists
299 ongoing studies on mTOR and cancer, 17 being
studies on mTOR and glioma, mostly testing the dual
inhibition of mTORC1 and mTORC2.
Recently, a direct role of mTOR in the modulation of
glial functions has also been described. Data from our
group and others support the notion that mTOR is
involved in glial proinflammatory activation [13-15]. In
particular, we have demonstrated that mTOR inhibitors
reduce iNOS expression and activity induced by cytokines,
but not those induced by lipopolysaccharide (LPS), in
primary rat microglia [13]. Among glioma-infiltrating
cells, microglia/macrophages represent the largest popula-
tion, contributing to the total tumor mass by at least one
third [16]. Under pathological conditions, these cells do
not constitute a uniform cell population, but rather
comprise a family of cells with diverse phenotypes
and opposite biological activities: beneficial or, on the
contrary, detrimental [17]. Macrophages and activated
microglia, the latter defined as CNS macrophages,
can be broadly divided into classically activated M1
cells, with cytotoxic properties, and alternatively activated
M2 cells, with phagocytic activities. Macrophages infiltrat-
ing tumor tissues are polarized by tumor-derived and
T-cell-derived cytokines towards an M2 phenotype [18]. In
general, it is now well-established that tumor-associated
macrophages promote tumor growth and progression [19].
As far as microglia and gliomas are specifically concerned,
under the influence of glioma M2 microglia releaseseveral classes of molecules that foster glioma growth
[20], progression and inflammatory activation [21] as
opposed classically activated microglia, the M1 pheno-
type, release inflammatory products, such as nitrites,
IL-10 and urea, that may exert detrimental effects on
glioma cells. We have recently found that microglial
cells undergo a different pattern of activation depend-
ing on the stimulus; in the presence of inflammatory
activated glioma-derived factors, that is, a condition
mimicking the late stage of pathology, microglial cells
appear as a mixture of polarization phenotypes (M1 and
M2a/b). At variance, microglia exposed to basal glioma-
derived factors, that is, a condition resembling the early
stage of pathology, show a more specific pattern of activa-
tion, with increased M2b polarization status [22].
The tuberous sclerosis complex (TSC)-mTOR pathway
regulates macrophage polarization [23]; in particular, it
seems that mTOR activation leads to M2 polarization. In
fact, bone morphogenetic protein-7 (BMP-7) mediates
monocyte polarization into M2 macrophages through the
activation of the PI3K-AKT-mTOR pathway [24] and
RAPA, by blocking mTOR, and unbalances the polarization
of human macrophages towards the M1 status [25].
In the present paper, we have compared the effects
of μM concentrations of RAPA and its analog, RAD,
on activated microglia, in the attempt to block both
mTORC1 and mTORC2 functions [26]. Microglial
activation was obtained by exposing cells to conditioned
medium harvested either from inflammatory activated
glioma cells (LI-CM) or from glioma cells kept under
basal conditions (C-CM) [20]. Consistent with the
findings in peripheral macrophages, here we show that the
inhibition of mTOR polarizes glioma-activated microglial
cells towards the M1 phenotype endowed with cytotoxic
activities, thus preventing the induction of the M2 status
that promotes tumor growth.
Methods
Materials
Cell culture reagents (DMEM, DMEM-F12 and FCS)
were from Invitrogen Corporation (Paisley, Scotland).
Antibiotics were from Biochrom AG (Berlin, Germany).
The rat recombinant IFNγ was purchased from Endogen
(Pierce Biotechnology, Rockford, IL, USA). Bacterial
endotoxin LPS (Salmonella typhimurium) was from
Sigma-Aldrich (St Louis, MO, USA). β-actin (clone AC-74)
mouse monoclonal antibody was from Sigma Aldrich;
rabbit polyclonal anti-phospho (ser-2448) mTOR were
purchased from Novus Biological (Littleton, CO, USA).
Cell cultures
Microglia
Primary enriched cultures of rat glial cells, microglia and
astrocytes, were prepared as previously described [27].
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cultures of cortical glial cells (at day 14 in vitro) by
gentle shaking. Cells were plated in 96-well plates at a
density of 3 × 105 cells/cm2 using 100 μL/well DMEM-F12,
containing 10% FCS and antibiotics. Under these con-
ditions, the cultures were 95 to 98% CD11b-positive
[28]. The use of animals for this experimental work
has been approved by the Ethics Committee of the
Catholic University Medical School.C6 glioma cells
C6 glioma cells were passed once a week and were
prepared as previously described [14]. Conditioned
media from activated C6 glioma cells were generated
following a protocol aimed to remove the proinflammatory
stimulus from the medium [22]. Briefly, control-conditioned
medium (C-CM) was obtained incubating C6 glioma cells
for 4 h in plain medium, and after three washes with PBS in
fresh plain medium for an additional 24 h. After this second
period of incubation, the CM was collected, centrifuged to
remove cellular debris and stored as C-CM. Similarly,
LPS/IFNγ-conditioned medium (LI-CM) was prepared
incubating C6 cells for 4 h with LI, followed after
three washes with PBS by 24-h incubation in fresh
plain medium. LI-CM was collected, centrifuged and
stored after this second period of incubation, thus LI-CM
did not contain the proinflammatory stimuli used to acti-
vate glioma cells. Both CM were stored at −80°C until the
experiments on microglial cells were performed.Nitrite assay
Inducible nitric oxide synthase (iNOS) activity was
assessed indirectly by measuring nitrite accumulation in
the incubation media. Briefly, an aliquot of the cell cul-
ture media (80 μL) was mixed with 40 μL Griess Reagent
(Sigma-Aldrich) and the absorbance measured at 550 nm
in a spectrophotometric microplate reader (PerkinElmer
Inc, Waltham MA, USA). A standard curve was generated
during each assay in the range of concentrations 0 to
100 μM using NaNO2 (Sigma-Aldrich) as the standard. In
this range, standard detection produced a linear distribu-
tion and the minimum detectable concentration of NaNO2
was ≥3.12 μM. In the absence of stimuli basal levels ofTable 1 Primer sets used for Q-PCR analysis
Genes Forward primers
α-TUB CCC TCG CCA TGG TAA ATA CAT ACT GG
iNOS CTG CAT GGA ACA GTA TAA GGC AAA C CAG AC
IL-10 CAG CTG CGA CGC TGT CAT CGA GCA GT
ARG1 TGC CCT CTG TCT TTT AGG GC CCT CG
Raptor GCA GGC CTG GGA CCT TGC TG CGA CA
Rictor AGC AGT GAT CCG AAA GGA GGG AAA TAC TTnitrites were below the detection limit of the assay at all
the time points studied.mRNA analysis in real-time PCR
Total cytoplasmic RNA was extracted using the RNeasy
Micro kit (Qiagen, Hilden, Germany), which included
15 minutes of DNAse treatment. RNA concentration was
measured using the Quant-iTTM RiboGreen® RNA Assay
Kit (Invitrogen Corporation, Carlsbad, CA, USA). A stand-
ard curve in the range of 0 to 100 ng was run in each assay
using 16S and 23S ribosomal RNA (rRNA) from Escheri-
chia coli as standard and provided by the kit. Aliquots
(0.15 μg) of RNA were converted to cDNA using random
hexamer primers. Quantitative changes in mRNA levels
were estimated by real time PCR (Q-PCR) using the follow-
ing cycling conditions: 35 cycles of denaturation at 95°C for
20 s; annealing and extension at 60°C for 20 s, using the
Brilliant III Ultra-Fast SYBR® Green QPCR Master Mix
(Stratagene, La Jolla, CA, USA), except for Raptor gene ex-
pression (35 cycles of denaturation at 95°C for 20 s; anneal-
ing 64°C and extension at 60°C for 20 s, using the Brilliant
II SYBR® Green QPCR Master Mix). PCR reactions were
carried out in a 20-μL reaction volume in a MX3000P
real-time PCR machine (Stratagene). Primers used for the
evaluation of gene expression are reported in Table 1. Rela-
tive mRNA concentrations were calculated from the take-
off point of reactions (threshold cycle, Ct) using the com-
parative quantitation method performed by Stratagene
software and based upon the -ΔΔCt method [13].Cell viability measurement
Microglial viability was assessed by reduction of the
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-
(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) contained
in the CellTiter AQueous One Solution Reagent (Promega,
Madison, WI, USA). For this assay cells were seeded
in 96-well plates. At the end of the experimental procedure
(46 h), 20 μL of MTS reagent were added to the cells
that were further incubated for 2 h. Living cells bio-
reduce yellow MTS into a purple soluble formazan
product with an absorbance peak at 492 nm, that was read
in a spectrophotometric microplate reader (PerkinElmer
Inc, MA, USA).Reverse primers Product length (Base pair)
A TGG TAC GCT TGG TCT 110
A GTT TCT GGT CGA TGT CAT GA 230
C CAG TAG ATG CCG GGT G 198
A GGC TGT CCC TTA GA 165
G GGC CAA GCT CAC CG 271
G GAG TGC TGC CAG TGT CTT 199
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Microglial proliferation rate was determined using a
nonradioactive proliferation assay (Exalpha Biological
Inc, Maynard, MA, USA), used according to the
manufacturer’s instructions. This ELISA measures the
incorporation of 5-bromo-2-deoxyuridine (BrdU) into
newly synthesized DNA of actively proliferating cells.
Microglial cells were incubated in plain medium or C-
CM, LI-CM for 48 h. BrdU solution was added 32 h
later directly in the incubation medium, and cells were
kept in the incubator for the remaining 16 h. At the end
of the incubation time, medium was removed and cells were
fixed. !BrdU immunoreactivity was measured using a
specific primary antibody provided by the kit. Data are
expressed as percentage of control values.Western immunoblot
The cells were lysed in RIPA buffer (1 mM EDTA,
150 mM NaCl, 1% igepal, 0.1% sodium dodecyl
sulfate, SDS, 0.5% sodium deoxycholate, 50 mM
Tris–HCl, pH 8.0) (Sigma-Aldrich) containing prote-
ase inhibitor cocktail diluted 1:250 (Sigma-Aldrich).
The protein content in each sample was determined
by Bradford’s method (Biorad, Hercules, CA, USA)
using bovine serum albumin as the standard. A 10-μg
aliquot of protein was mixed 1:2 with 2 × Laemmli
Buffer (Biorad), boiled for 5 minutes, and separated
through 7% polyacrylamide SDS gels. Apparent mo-
lecular weights were estimated by comparison to
colored molecular-weight markers (Sigma-Aldrich).
After electrophoresis, proteins were transferred to
polyvinylidene difluoride membranes by semi-dry elec-
trophoretic transfer (Biorad). The membranes were
blocked with 10% (w/v) low-fat milk in TBST (10 mMTris,
150 mMNaCl, 0.1% Tween-20, pH 7.6) (Biorad) for 1 h at
room temperature, and incubated in the presence of the
primary antibody overnight with gentle shaking at 4°C. Pri-
mary antibodies for phosphorylated-mTOR (Novus bio-
logical), β-actin (Sigma-Aldrich) were used at the final
concentration of 1:1,000. Primary antibodies were re-
moved, membranes washed three times in TBST, and
further incubated for 1 h at room temperature in the
presence of specific secondary antibody, anti-rabbit for
mTOR and anti-mouse for β-actin immunoglobulin G
(IgG)-horseradish peroxidase (HRP)-conjugated (Sigma-
Aldrich), diluted 1:15,000 and 1:10,000 respectively.
Following three washes in TBST, bands were visualized
by incubation in ECL reagents (Thermo Scientific,
Rockford, Illinois, USA) and exposure to Hyperfilm
ECL (GE Healthcare NY, USA). The same membranes
were washed three times in TBST, blocked with 10%
(w/v) low-fat milk in TBST for 1 h at room
temperature and used for β-actin immunoblot.Data analysis
All experiments were performed using five to six replicates
per each experimental group, and repeated at least
three times. For the RNA analysis, samples were assayed
in triplicates, and the experiments were repeated at least
twice. Data were analyzed by one- or two-way ana-
lysis of variance (ANOVA) followed by Bonferroni
post hoc test or by the unpaired t-test where appropriate.
P-values <0.05 were considered significant.
Results
We have previously shown that CM harvested from
glioma cells under basal conditions (C-CM), as well as
CM from glioma cells activated with LPS/IFNγ (LI-CM),
increased the phosphorylation of mTOR at ser 2448, an
index of mTORC activation, in microglial cells in 2-h
experiments [21]. Here we confirmed this finding,
and also observed that mTOR activation is rapid and
time-persistent: after 30 minutes of incubation with
both conditioned media we detected an increase in
phospho-mTOR levels that persisted until 8 h (Figure 1).
However, no significant upregulation was found in the
mRNA levels of specific interactors of mTORC1 (raptor,
Figure 2A) and mTORC2 (rictor, Figure 2B) in 4- and
24-h experiments.
The administration of mTOR inhibitors (RAPA and
RAD) to microglial cells exposed to C-CM significantly
increased iNOS gene expression after 4 h (Figure 3A),
followed by an increase in the levels of NO after 48 h
(Figure 3B). Furthermore, RAPA and RAD were also able
to increase iNOS mRNA levels after 4 h in microglial cells
exposed to LI-CM (Figure 3C); such upregulation was
followed by a significant augmentation of NO production
after 48 h (Figure 3D).
In addition, both drugs reduced the upregulation of
IL-10 gene expression elicited by C-CM, with significant
inhibition from 4 h onward (Figure 4A). In parallel,
the drugs were able to reduce the upregulation of IL-10
(Figure 4B) and arginase (ARG) (Figure 4C) elicited by
LI-CM. Taken together, these data show that mTOR
blockade promotes M1 microglial polarization in both
experimental paradigms (that is, conditions resembling
the early stage of pathology and conditions mimicking the
late stage of pathology).
A subsequent set of experiments was carried out to
assess the effect of mTOR inhibitors on cell viability and
proliferation. First, we tested the direct effects of RAPA
and RAD on C6 glioma cells and confirmed that both
drugs reduce glioma viability (Figure 5A), as reported in
the literature. In particular, RAPA and RAD at 1 nM,
reduced C6 glioma viability by about 30% after 3 days of
treatment. Thereafter, we assessed the effect of mTOR in-
hibitors on microglia viability in cells exposed to glioma-
conditioned media. In this experimental model, RAPA and
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Figure 1 Analysis of mammalian target of rapamycin (mTOR) phosphorylation during microglial activation. Whole-cell lysates were
prepared from microglial cells activated by control-conditioned medium (C-CM) (A) or CM from glioma cells activated with lipopolysaccharide
(LPS)/IFNγ (LI-CM) (B). Equal amounts of proteins were analyzed by western blot for phosphorylated mTOR kinase (p-mTOR), upper gel and were
subsequently probed for β-actin, lower gel. Quantitation of densitometry where p-mTOR values are reflected relative to those for β-actin. Data are
expressed as means ± standard error of the mean of n = 1 replicate for each group, each assayed in triplicate: representative of two different
experiments. Data were analyzed by one-way analysis of variance followed by Bonferroni post hoc test. ***P <0.001 versus control.
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ity induced by the exposure to C-CM or LI-CM,
although significantly higher concentrations (approximately
1,000-fold higher) were required to achieve a 50% reduc-
tion with respect to those found effective on C6 glioma
cells (Figure 5B and C) or else on microglial cells notFigure 2 Effects of the conditioned media on raptor and rictor expres
cells treated with control-conditioned medium (C-CM) or CM from glioma
times, and used for real time (Q)-PCR analysis of raptor (A) and rictor (B) ex
calibrator for comparative quantitation analysis of mRNA levels. Each sample w
similar results. Data are means ± standard error of the mean, and were analyzexposed to glioma factors [13]. In untreated microglia, via-
bility was significantly affected by mTOR inhibition even
at a low dose (from 10 nM concentration onward) [13].
No significant differences were observed in microglia
proliferation in the presence of mTOR inhibitors in
the two different experimental paradigms (Figure 6).sion. Total cytosolic RNA was prepared from control, or microglial
cells activated with lipopolysaccharide (LPS)/IFNγ (LI-CM) for different
pression. Data are expressed as fold change versus control, taken as
as measured in triplicate and the experiment was repeated twice with
ed by two-way analysis of variance followed by Bonferroni post hoc test.
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Figure 3 Effects of mammalian target of rapamycin (mTOR) inhibitors on nitric oxide synthase (NOS)2 in microglia stimulated by both
control-conditioned medium (C-CM) and CM from glioma cells activated with LPS/IFNγ (LI-CM). Cells were treated with C-CM alone or in
combination with mTOR inhibitors. (A-B) and with LI-CM alone or in combination with mTOR inhibitors (C-D). Total cytosolic RNA was prepared
from control, or microglial cells treated with the drugs for 4 h, and used for real time (Q)-PCR analysis of NOS2 expression. Data are expressed as
fold change versus control, taken as calibrator for comparative quantitation analysis of mRNA levels. Each sample was measured in triplicate and
the experiment was repeated three times with similar results. Data are means ± standard error of the mean (SEM), and were analyzed by one-way
analysis of variance followed by Bonferroni post hoc test. ***P <0.001 versus control; °P <0.05 °°°P <0.001 versus C-CM and °P <0.05 °°P <0.01 versus LI-CM.
(B-D) After 48-h incubation, the medium was used for nitrite assessment, whereas cells were lysed in 200 mM NaOH and protein content was evaluated
by the Bradford method. Results are expressed as μM of nitrites/μg of proteins; data are means ± SEM (n = 6). *P <0.05, ***P <0.001 versus C-CM; *P <0.05
versus control and °P <0.001 °°°P <0.001 versus LI-CM.
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In this study we evaluated the effects of mTOR inhibitors
on microglial polarization in experimental models of
glioma-microglia interaction. We have compared the
effects of RAPA and its analog RAD on primary rat
microglia activated by conditioned medium harvested
from C6 glioma cultures in two different conditions.
Drugs were administrated at high doses (0.01 to 10 μM
concentrations), attempting to block the activity of both
mTOR complexes. In fact, it was previously shown that
RAPA given at higher concentrations and in chronic
treatments also interferes with mTORC2 regulatory
functions [26]. In particular, high intracellular levels
of RAPA inhibit the binding and subsequent assembly
of mTORC2-specific components Sin1 and rictor [24].
Rictor is a core component of mTORC2; we found
that rictor is expressed in microglia cells, albeit its
expression is not modulated by the exposure to eitherLI-CM or C-CM glioma-conditioned media (Figure 2B).
Consistently with the literature, we found that microglial
cells express the specific component of mTORC1, raptor,
whose expression was also unaffected by the exposure to
glioma factors (Figure 2A).
The crosstalk among mTORC1 and mTORC2 occurring
in microglia cells ensures a correct balance between cell
growth and division, regulating important intracellular
metabolic processes and possibly different types of activa-
tion, as it is observed in other immune cells [29]. The acti-
vation of mTORC1 generally increases the cellular capacity
of protein and lipid biosynthesis, and inhibits macroauto-
phagy, thus promoting anabolic processes [1]. Hence it is
not surprising that mTORC1 is deregulated in many tumor
types, including malignant gliomas [11]. Several oncogenes
(PI3K, AKT or Ras) and/or tumor suppressors (PTEN,
LKB1, or TSC1/2), which are often mutated in cancer, con-
tribute to control mTORC1 activation [3]. mTORC1 and
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Figure 4 Effects of mammalian target of rapamycin (mTOR) inhibitors on M2 markers in microglia stimulated by both control-conditioned
medium (C-CM) and LI-CM. Cells were treated with control-conditioned medium (C-CM) or CM from glioma cells activated with lipopolysaccharide
(LPS)/IFNγ (LI-CM) and mTOR inhibitors. Total cytosolic RNA was prepared from control, or microglial cells treated with C-CM alone or with mTOR
inhibitors for 4 h (A) and with LI-CM alone or with mTOR inhibitors for 4 h (B) or 24 h (C), and used for real time (Q)-PCR analysis of IL-10 (A-B) and
arginase (ARG)1 (C) expression. Data are expressed as fold change versus control, taken as calibrator for comparative quantitation analysis of mRNA
levels. Each sample was measured in triplicate and the experiment was repeated three times with similar results. Data are means ± standard error of
the mean, and were analyzed by one-way analysis of variance followed by Bonferroni post hoc test. ***P <0.001 versus control and °°°P <0.001,
°P <0.05, versus C-CM; ***P <0.001 versus control and °°P <0.01 versus LI-CM.
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ness and cell migration [5,30]. mTORC2 activity is elevated
in gliomas and promotes growth and cell motility via the
overexpression of rictor [31], although it has been reported
that rictor silencing by siRNAs in human glioma cell lines
and primary GBM cells induces MMP-9 activity and
enhances the invasive potential of glioma cells through the
Raf-1-MEK-ERK signaling pathway [32].
The available evidence on the role of microglia in CNS
cancers would suggest a dual role, a tumoricidal role
and, on the contrary, a role favoring tumor growth, as
described in detail in the Introduction section. A further
viewpoint arises from the recent finding that subpopulations
of cells within human gliomas, specifically GBM, are
neoplastic macrophages/microglia [33]. Metastatic cancer
cells retrieved in spontaneous mouse brain tumors appear
to express multiple properties of macrophages [34], thus
suggesting that the most aggressive cells in GBM may be
neoplastic microglia/macrophages. In this regard, fusion
of tumor cells with microglial cells has been proposed as a
mechanism underlying invasion and metastasis in GBM,as it occurs in several human cancers [33]. In this scenario,
data presented in this paper suggest that the inhibition of
mTOR in microglial cells, apart from the more relevant
antitumor effects mediated by the polarization of micro-
glia towards an M1 phenotype (Figure 3), while on the
same time polarization towards the M2 status is prevented
(Figure 4), might also result in anti-proliferative activity
directly on neoplastic microglia.
Microglial cells in the M1 status release proinflammatory
cytokines, proteinases, complement proteins, prostaglan-
dins, and reactive oxygen intermediates, including nitric
oxide. These substances can exert toxic effects on glioma
cells and hence contribute to their destruction. Nitric
oxide, for example, has emerged as a powerful adjuvant for
the hyper-sensitization of tumors to more traditional
chemo- and radio-therapeutics. Furthermore, emerging
evidence indicates that nitric oxide donors have the poten-
tial to exert intrinsic antitumor activity in the clinical
management of cancer [35]. However, while the above dis-
cussion would suggest an overall favorable role for M1
polarization of microglia, it should be taken into account
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Figure 5 Effects of mammalian target of rapamycin (mTOR) inhibitors on cell viability. (A) C6 glioma cells were administrated with mTOR
inhibitors. Microglia cells were treated for 48 h with control-conditioned medium (C-CM) (B) or CM from glioma cells activated with lipopolysaccharide
(LPS)/IFNγ (LI-CM) (C) and mTOR inhibitors. Effects on cell viability were assessed by the MTS reduction assay. Data were analyzed by one-way analysis
of variance followed by Bonferroni post hoc test. ***P <0.001, versus Control, °°°P <0.001 versus C-CM or LI-CM.
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http://www.jneuroinflammation.com/content/11/1/125that the latter may also have detrimental effects, as it has
been shown that chronic activation of microglia can cause
damage to normal neurons through the release of
the same substances that are potentially cytotoxic for
glioma cells [36].
In conclusion, the main finding of this study is the
observation that mTOR inhibition by RAPA and RAD0
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tumoricidal properties is a mechanism of potential
interest in light of a possible clinical development of
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